{"id":76349,"date":"2026-08-24T11:32:46","date_gmt":"2026-08-24T03:32:46","guid":{"rendered":"https:\/\/flcube.com\/?p=76349"},"modified":"2026-08-24T11:32:48","modified_gmt":"2026-08-24T03:32:48","slug":"henlius-h1-2026-earnings-trastuzumab-sales-surge-27-3-revenue-growth-as-overseas-profit-quadruples","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76349","title":{"rendered":"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Henlius Biotech, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2696:HKG\">HKG: 2696<\/a>) released its first-half 2026 results, reporting <strong>total revenue of RMB 3.5882 billion<\/strong>, up <strong>27.3% year-on-year<\/strong>, and <strong>net profit of RMB 430.4 million<\/strong>, up <strong>10.3% YoY<\/strong>, driven by its trastuzumab-anchored breast cancer franchise and rapidly expanding overseas commercialization.<\/p>\n\n\n\n<h2 id=\"h-financial-highlights\" class=\"wp-block-heading\">Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>H1 2026<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 3.5882 bn<\/td><td><strong>+27.3%<\/strong><\/td><\/tr><tr><td><strong>Net Profit<\/strong><\/td><td>RMB 430.4 m<\/td><td><strong>+10.3%<\/strong><\/td><\/tr><tr><td><strong>Global Product Sales<\/strong><\/td><td>RMB 2.9386 bn<\/td><td><strong>+14.9%<\/strong><\/td><\/tr><tr><td><strong>Overseas Product Sales<\/strong><\/td><td>RMB 105.3 m<\/td><td><strong>+159.4%<\/strong><\/td><\/tr><tr><td><strong>Overseas Product Profit<\/strong><\/td><td>RMB 59.5 m<\/td><td><strong>&gt;4x YoY<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-breast-cancer-franchise-trastuzumab-leads\" class=\"wp-block-heading\">Breast Cancer Franchise \u2013 Trastuzumab Leads<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Breast cancer therapeutic area revenue reached <strong>RMB 1.6983 billion<\/strong>, approximately <strong>58% of global product sales<\/strong>, powered by four approved products:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Molecule (Brand ex-China)<\/th><th>H1 2026 Sales<\/th><\/tr><\/thead><tbody><tr><td><strong>HANQUYOU<\/strong><\/td><td>Trastuzumab (HERCESSI, US; Zercepac, EU)<\/td><td><strong>RMB 1.4844 bn<\/strong><\/td><\/tr><tr><td><strong>HANNAIJIA<\/strong><\/td><td>Neratinib<\/td><td>RMB 195.5 m<\/td><\/tr><tr><td><strong>FUTUONING<\/strong><\/td><td>Fovecitinib<\/td><td>RMB 10.7 m<\/td><\/tr><tr><td><strong>HANBEIYOU<\/strong><\/td><td>Pertuzumab (POHERDY, US\/EU)<\/td><td>RMB 7.7 m<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-solid-tumor-portfolio-multi-product-momentum\" class=\"wp-block-heading\">Solid Tumor Portfolio \u2013 Multi-Product Momentum<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Molecule<\/th><th>H1 2026 Performance<\/th><\/tr><\/thead><tbody><tr><td><strong>HANSIZHUANG<\/strong><\/td><td>Serplulimab (Hetronifly, EU)<\/td><td>Global sales of RMB 597.5 m<\/td><\/tr><tr><td><strong>HANBEITAI<\/strong><\/td><td>Bevacizumab<\/td><td>RMB 218.2 m, <strong>+87.6% YoY<\/strong>; U.S. BLA approval expected in H2 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-mature-products-amp-denosumab-stable-cash-flow\" class=\"wp-block-heading\">Mature Products &amp; Denosumab \u2013 Stable Cash Flow<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HANLIKANG (rituximab):<\/strong> RMB 335.7 m in sales and licensing revenue under partner agreements<\/li>\n\n\n\n<li><strong>HANDAYUAN (adalimumab):<\/strong> RMB 30.4 m in sales and licensing revenue<\/li>\n\n\n\n<li><strong>HLX14 (denosumab):<\/strong> RMB 73.1 m contribution; two specifications \u2014 <strong>BILDYOS<\/strong> (60 mg\/mL) and <strong>BILPREVDA<\/strong> (120 mg\/1.7 mL) \u2014 approved in the <strong>U.S., EU and U.K.<\/strong> in H2 2025<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-amp-regulatory-progress\" class=\"wp-block-heading\">Clinical &amp; Regulatory Progress<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>In-house Teams<\/strong><\/td><td>U.S., Europe, Japan, Australia<\/td><\/tr><tr><td><strong>Concurrent Trial Geography<\/strong><\/td><td>~30 countries and regions<\/td><\/tr><tr><td><strong>Partner Trial Centers<\/strong><\/td><td>1,000+<\/td><\/tr><tr><td><strong>New IND Approvals (H1)<\/strong><\/td><td>32<\/td><\/tr><tr><td><strong>New MAA Approvals (H1)<\/strong><\/td><td>25<\/td><\/tr><tr><td><strong>Regulatory Coverage<\/strong><\/td><td>~50 countries and regions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-manufacturing-amp-supply\" class=\"wp-block-heading\">Manufacturing &amp; Supply<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>1,400+<\/strong> commercial production batches completed under GMP standards<\/li>\n\n\n\n<li><strong>100+<\/strong> on-site inspections by global regulators and partners \u2014 <strong>100% pass rate<\/strong><\/li>\n\n\n\n<li><strong>9<\/strong> first-to-market product launches executed in H1<\/li>\n\n\n\n<li><strong>18<\/strong> overseas bulk shipments completed<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Overseas Inflection Point:<\/strong> Overseas profit more than quadrupling YoY on a 159.4% sales surge signals Henlius&#8217;s global commercialization is transitioning from licensing deals toward scalable product economics.<\/li>\n\n\n\n<li><strong>U.S. Catalyst Ahead:<\/strong> A positive H2 2026 decision on the bevacizumab BLA would add a second major U.S. commercial asset alongside HLX14 denosumab, which secured U.S., EU and U.K. approvals in late 2025 and is already contributing revenue.<\/li>\n\n\n\n<li><strong>Trastuzumab Dependency:<\/strong> HANQUYOU accounts for ~50% of global product sales, keeping concentration risk in focus even as pertuzumab, neratinib and fovecitinib build the broader breast cancer portfolio.<\/li>\n\n\n\n<li><strong>Pipeline Velocity:<\/strong> 32 IND and 25 MAA approvals in a single half-year across ~50 countries support continued multi-market launch cadence into 2027.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory decisions, product launches, and commercial expectations for Henlius and its portfolio. Actual results may differ due to risks including regulatory timelines, market adoption, pricing dynamics, and competitive pressures.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Henlius1H26ResultsInvestorPresentation.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Henlius1H26ResultsInvestorPresentation.\"><\/object><a id=\"wp-block-file--media-d1495ed2-96c3-4c4a-bbf1-5100d1303b9c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Henlius1H26ResultsInvestorPresentation.pdf\">Henlius1H26ResultsInvestorPresentation<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/Henlius1H26ResultsInvestorPresentation.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d1495ed2-96c3-4c4a-bbf1-5100d1303b9c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76353,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,270,862],"class_list":["post-76349","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-henlius-biotech","tag-hkg-2696"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of RMB 3.5882 billion, up 27.3% year-on-year, and net profit of RMB 430.4 million, up 10.3% YoY, driven by its trastuzumab-anchored breast cancer franchise and rapidly expanding overseas commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76349\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of RMB 3.5882 billion, up 27.3% year-on-year, and net profit of RMB 430.4 million, up 10.3% YoY, driven by its trastuzumab-anchored breast cancer franchise and rapidly expanding overseas commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76349\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T03:32:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-24T03:32:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76349#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76349\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples\",\"datePublished\":\"2026-08-24T03:32:46+00:00\",\"dateModified\":\"2026-08-24T03:32:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76349\"},\"wordCount\":442,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76349#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2401.webp\",\"keywords\":[\"Finanical Reports\",\"Henlius Biotech\",\"HKG: 2696\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76349#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76349\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76349\",\"name\":\"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76349#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76349#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2401.webp\",\"datePublished\":\"2026-08-24T03:32:46+00:00\",\"dateModified\":\"2026-08-24T03:32:48+00:00\",\"description\":\"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of RMB 3.5882 billion, up 27.3% year-on-year, and net profit of RMB 430.4 million, up 10.3% YoY, driven by its trastuzumab-anchored breast cancer franchise and rapidly expanding overseas commercialization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76349#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76349\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76349#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2401.webp\",\"width\":1080,\"height\":608,\"caption\":\"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76349#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of RMB 3.5882 billion, up 27.3% year-on-year, and net profit of RMB 430.4 million, up 10.3% YoY, driven by its trastuzumab-anchored breast cancer franchise and rapidly expanding overseas commercialization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76349","og_locale":"en_US","og_type":"article","og_title":"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples","og_description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of RMB 3.5882 billion, up 27.3% year-on-year, and net profit of RMB 430.4 million, up 10.3% YoY, driven by its trastuzumab-anchored breast cancer franchise and rapidly expanding overseas commercialization.","og_url":"https:\/\/flcube.com\/?p=76349","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-24T03:32:46+00:00","article_modified_time":"2026-08-24T03:32:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76349#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76349"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples","datePublished":"2026-08-24T03:32:46+00:00","dateModified":"2026-08-24T03:32:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76349"},"wordCount":442,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76349#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2401.webp","keywords":["Finanical Reports","Henlius Biotech","HKG: 2696"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76349#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76349","url":"https:\/\/flcube.com\/?p=76349","name":"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76349#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76349#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2401.webp","datePublished":"2026-08-24T03:32:46+00:00","dateModified":"2026-08-24T03:32:48+00:00","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of RMB 3.5882 billion, up 27.3% year-on-year, and net profit of RMB 430.4 million, up 10.3% YoY, driven by its trastuzumab-anchored breast cancer franchise and rapidly expanding overseas commercialization.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76349#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76349"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76349#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2401.webp","width":1080,"height":608,"caption":"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76349#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2401.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76349"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76349\/revisions"}],"predecessor-version":[{"id":76356,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76349\/revisions\/76356"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76353"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}